輝隆股份(002556.SZ):擬註冊發行不超8億元中期票據及不超4億元超短期融資券
格隆匯7月6日丨輝隆股份(002556.SZ)公佈,為進一步拓寬公司的融資渠道、優化資金結構,結合當前的金融市場環境,安徽輝隆農資集團股份有限公司於2022年7月6日召開第五屆董事會第十一次會議審議通過了《公司關於擬申請註冊發行中期票據及超短期融資券的議案》。
此次擬發行的中期票據申請註冊總額度為不超過人民幣8億元(含8億元);此次擬發行的超短期融資券申請註冊總額度為不超過人民幣4億元(含4億元),具體發行規模根據在中國銀行間市場交易商協會(以下簡稱“交易商協會”)最終註冊的金額、資金需求和市場情況確定。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.